Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG): Updated follow-up from KEYNOTE-057.

被引：2
|
作者：
De Wit, Ronald
Kulkarni, Girish S.
Uchio, Edward M.
Krieger, Laurence Eliot Miles
Boormans, Joost L.
Roumiguie, Mathieu
Singer, Eric A.
Bajorin, Dean F.
Kamat, Ashish M.
Grivas, Petros
Seo, Ho Kyung
Nishiyama, Hiroyuki
Konety, Badrinath R.
Nam, Kijoeng
Kapadia, Ekta
Frenkl, Tara L.
Balar, Arjun Vasant
机构：
[1] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[2] Univ Toronto, UHN Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] UC Irvine Hlth, Orange, CA USA
[4] Royal North Shore Hosp, Northern Canc Inst, St Leonards, NSW, Australia
[5] Inst Univ Canc Toulouse Oncopole CHU, Toulouse, France
[6] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Univ Washington, Seattle, WA 98195 USA
[10] Natl Canc Ctr, Goyang, South Korea
[11] Univ Tsukuba, Tsukuba, Ibaraki, Japan
[12] Univ Minnesota, Minneapolis, MN USA
[13] Merck & Co Inc, Kenilworth, NJ USA
[14] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.4530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4530
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guerin (BCG) unresponsive, high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.
    Balar, Arjun Vasant
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Bajorin, Dean F.
    Roumigui, Mathieu
    Singer, Eric A.
    Krieger, Laurence Eliot Miles
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Zambon, Joao Paulo
    Kapadia, Ekta
    De Wit, Ronald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG).
    Balar, Arjun Vasant
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost
    Mourey, Loic
    Krieger, Laurence Eliot Miles
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    De Wit, Ronald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)
    de Wit, R.
    Kulkarni, G. S.
    Uchio, E.
    Boormans, J. L.
    Roumiguie, M.
    Krieger, L. E. M.
    Singer, E. A.
    Bajorin, D. F.
    Kamat, A. M.
    Grivas, P.
    Seo, H. K.
    Nishiyama, H.
    Konety, B. R.
    Saretsky, T.
    Li, H.
    Nam, K.
    Sbar, E.
    Balar, A. V.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [4] Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial
    de Wit, R.
    Kulkarni, G. S.
    Uchio, E.
    Singer, E. A.
    Krieger, L.
    Grivas, P.
    Bajorin, D.
    Seo, H. K.
    Mourey, L.
    Kamat, A.
    Nishiyama, H.
    Kapadia, E.
    Nam, K.
    Frenkl, T.
    Balar, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 304 - 304
  • [5] Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
    Krieger, Laurence
    de Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 52 - 53
  • [6] Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin: Extended follow-up of KEYNOTE-057 cohort A.
    Balar, Arjun Vasant
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Krieger, Laurence Eliot Miles
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Zambon, Joao Paulo
    Kapadia, Ekta
    De Wit, Ronald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [7] KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)
    Kamat, Ashish M.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Nam, Kijoeng
    De Santis, Maria
    Dreicer, Robert
    Hahn, Noah M.
    Perini, Rodolfo F.
    Siefker-Radtke, Arlene O.
    Sonpavde, Guru
    De Wit, Ronald
    Witjes, Alfred
    Keefe, Stephen Michael
    Bajorin, Dean F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guerin (BCG)-unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Gupta, S.
    Kulkarni, G.
    Necchi, A.
    Shore, N. D.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    [J]. EUROPEAN UROLOGY, 2024, 85 : S433 - S433
  • [9] OUTCOMES IN PATIENTS (PTS) WITH BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE HIGH-RISK (HR) NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) WHO UNDERWENT RADICAL CYSTECTOMY (RC) FOLLOWING PEMBROLIZUMAB (PEMBRO) TREATMENT IN KEYNOTE-057 COHORT A
    Kulkarni, Girish S.
    Kamat, Ashish M.
    Uchio, Edward M.
    Roumiguie, Mathieu
    Krieger, Laurence E. M.
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    De Wit, Ronald
    Kapadia, Ekta
    Xing, Aiwen
    Fijlstra, Margot Van den Sigtenhorst
    Boormans, Joost L.
    [J]. JOURNAL OF UROLOGY, 2023, 209 : E872 - E873
  • [10] Pembrolizumab for the Treatment of Patients With Bacillus Calmette-Guerin-Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer: Over 2 Years' Follow-Up of KEYNOTE-057.
    Krieger, Laurence Eliot Miles
    Balar, Arjun Vasant
    Ashish, Kamat
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Bajorin, Dean F.
    Roumiguie, Mathieu
    Singer, Eric A.
    Grivas, Petros
    Seo, Ho Kyung
    Hiroyuki, Nishiyama
    Konety, Badrinath R.
    Zambon, Joao Paulo
    Ekta, Kapadia
    de Wit, Ronald
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 47 - 47
12345